Swartz Robin 4

What Happened

• Robin Swartz, Chief Operating Officer & Chief Business Officer of Voyager Therapeutics (VYGR), disposed of 6,458 shares on 2026-02-24. The reported weighted-average price was $3.77 per share, for total proceeds of $24,347. The shares were sold under an automatic sell-to-cover instruction to satisfy tax withholding related to RSUs that vested on Feb 21, 2026; the sale was not a discretionary trade by the reporting person.

Key Details

• Transaction date: 2026-02-24; Form filed: 2026-02-26.
• Sale details: 6,458 shares sold; weighted-average price $3.77; sale prices ranged $3.61–$3.86 (sold in multiple transactions).
• Shares owned after transaction: not specified in the provided summary (see the Form 4 for post-transaction holdings).
• Footnotes: F1 — sale pursuant to durable automatic sell-to-cover instruction adopted 2025-05-12 to satisfy RSU tax withholding; F2 — weighted-average price reported, reporting person will provide per-price breakdown on request.
• Transaction code: S (Sale). No lateness flag indicated in the provided data.

Context

• This was a routine sell-to-cover tied to RSU vesting (tax withholding), not an open-market discretionary sell; such transactions are administrative and do not necessarily signal insider sentiment. Purchases or discretionary sales typically carry more signal for investor interpretation.